Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down – Here’s What Happened

Shares of Hypermarcas (OTCMKTS:HYPMY) gapped down prior to trading on Wednesday. The stock had previously closed at $5.3590, but opened at $5.10. Hypermarcas shares last traded at $5.40, with a volume of 333 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group raised Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

Hypermarcas Stock Performance

The stock’s 50-day moving average is $4.61 and its 200-day moving average is $4.42. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of 10.80 and a beta of 0.65. The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50.

Hypermarcas (OTCMKTS:HYPMY) last announced its earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, analysts expect that Hypermarcas will post 0.51 EPS for the current year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.